Evaluate The Lipid-Lowering Efficacy and Safety of Vytorin in Comparison With Atorvastatin in Hypercholesterolaemic Patients With Coronary Artery Disease

Trial Profile

Evaluate The Lipid-Lowering Efficacy and Safety of Vytorin in Comparison With Atorvastatin in Hypercholesterolaemic Patients With Coronary Artery Disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Atorvastatin
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms VYCAT
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 01 Sep 2010 Primary endpoint results presented at the ESC Congress 2010: Annual Congress of the European Society of Cardiology
    • 15 Dec 2009 Trial phase changed from III to IV as reported by ClinicalTrials.gov record.
    • 10 Nov 2009 Actual number of patients (229) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top